These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 9336418)

  • 21. Risk factors for abnormal hepatic enzyme elevation by methotrexate treatment in patients with rheumatoid arthritis: A hospital based-cohort study.
    Hakamata J; Hashiguchi M; Kaneko Y; Yamaoka K; Shimizu M; Maruyama J; Takeuchi T; Mochizuki M
    Mod Rheumatol; 2018 Jul; 28(4):611-620. PubMed ID: 29252093
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Rheumatoid arthritis associated with methotrexate-induced pneumonitis: improvement with i.v. cyclophosphamide therapy.
    Suwa A; Hirakata M; Satoh S; Mimori T; Utsumi K; Inada S
    Clin Exp Rheumatol; 1999; 17(3):355-8. PubMed ID: 10410272
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Certolizumab pegol in combination with dose-optimised methotrexate in DMARD-naïve patients with early, active rheumatoid arthritis with poor prognostic factors: 1-year results from C-EARLY, a randomised, double-blind, placebo-controlled phase III study.
    Emery P; Bingham CO; Burmester GR; Bykerk VP; Furst DE; Mariette X; van der Heijde D; van Vollenhoven R; Arendt C; Mountian I; Purcaru O; Tatla D; VanLunen B; Weinblatt ME
    Ann Rheum Dis; 2017 Jan; 76(1):96-104. PubMed ID: 27165179
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Adverse effects of low-dose methotrexate therapy in rheumatoid arthritis].
    Furuya T; Totokawa S; Nakajima A; Suzuki T; Kashiwazaki S
    Ryumachi; 1996 Oct; 36(5):746-52. PubMed ID: 8969553
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tocilizumab inhibits structural joint damage and improves physical function in patients with rheumatoid arthritis and inadequate responses to methotrexate: LITHE study 2-year results.
    Fleischmann RM; Halland AM; Brzosko M; Burgos-Vargas R; Mela C; Vernon E; Kremer JM
    J Rheumatol; 2013 Feb; 40(2):113-26. PubMed ID: 23322466
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Five-year outcomes of probable rheumatoid arthritis treated with methotrexate or placebo during the first year (the PROMPT study).
    van Aken J; Heimans L; Gillet-van Dongen H; Visser K; Ronday HK; Speyer I; Peeters AJ; Huizinga TW; Allaart CF
    Ann Rheum Dis; 2014 Feb; 73(2):396-400. PubMed ID: 23334213
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Spontaneous regression of lymphoproliferative disorders in patients treated with methotrexate for rheumatoid arthritis and other rheumatic diseases.
    Salloum E; Cooper DL; Howe G; Lacy J; Tallini G; Crouch J; Schultz M; Murren J
    J Clin Oncol; 1996 Jun; 14(6):1943-9. PubMed ID: 8656264
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy of leflunomide 100mg weekly compared to low dose methotrexate in patients with active rheumatoid arthritis. Double blind, randomized clinical trial.
    Jaimes-Hernández J; Meléndez-Mercado CI; Mendoza-Fuentes A; Aranda-Pereira P; Castañeda-Hernández G
    Reumatol Clin; 2012; 8(5):243-9. PubMed ID: 22763150
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Lack of association between CXCL9 and CXCL10 gene polymorphisms and the outcome of rheumatoid arthritis treatment with methotrexate.
    Kotrych D; Dziedziejko V; Safranow K; Pawlik A
    Eur Rev Med Pharmacol Sci; 2015 Aug; 19(16):3037-40. PubMed ID: 26367725
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Accelerated nodulosis during methotrexate therapy for refractory rheumatoid arthritis. A case report.
    Filosa G; Salaffi F; Bugatti L
    Adv Exp Med Biol; 1999; 455():521-4. PubMed ID: 10599392
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tocilizumab is clinically, functionally, and radiographically effective and safe either with or without low-dose methotrexate in active rheumatoid arthritis patients with inadequate responses to DMARDs and/or TNF inhibitors: a single-center retrospective cohort study (KEIO-TCZ study) at week 52.
    Izumi K; Kaneko Y; Yasuoka H; Seta N; Kameda H; Kuwana M; Takeuchi T
    Mod Rheumatol; 2015 Jan; 25(1):31-7. PubMed ID: 24684408
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Longterm methotrexate use in rheumatoid arthritis: 12 year followup of 460 patients treated in community practice.
    Wluka A; Buchbinder R; Mylvaganam A; Hall S; Harkness A; Lewis D; Littlejohn GO; Miller MH; Ryan PF
    J Rheumatol; 2000 Aug; 27(8):1864-71. PubMed ID: 10955325
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Methotrexate combined with isoniazid treatment for latent tuberculosis is well tolerated in patients with rheumatoid arthritis: experience from an urban arthritis clinic.
    Mor A; Bingham CO; Kishimoto M; Izmirly PM; Greenberg JD; Reddy S; Rosenthal PB
    Ann Rheum Dis; 2008 Apr; 67(4):462-5. PubMed ID: 17711866
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Interstitial lung diseases induced or exacerbated by DMARDS and biologic agents in rheumatoid arthritis: a systematic literature review.
    Roubille C; Haraoui B
    Semin Arthritis Rheum; 2014 Apr; 43(5):613-26. PubMed ID: 24231065
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Open-label observation of addition of etanercept versus a conventional disease-modifying antirheumatic drug in subjects with active rheumatoid arthritis despite methotrexate therapy in the Latin American region.
    Machado DA; Guzman RM; Xavier RM; Simon JA; Mele L; Pedersen R; Ferdousi T; Koenig AS; Kotak S; Vlahos B
    J Clin Rheumatol; 2014 Jan; 20(1):25-33. PubMed ID: 24356474
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Adverse effects of low dose methotrexate in rheumatoid arthritis patients. A hospital-based study.
    Attar SM
    Saudi Med J; 2010 Aug; 31(8):909-15. PubMed ID: 20714691
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Risk factors associated with the cumulative survival of low-dose methotrexate in 273 Japanese patients with rheumatoid arthritis.
    Ideguchi H; Ohno S; Ishigatsubo Y
    J Clin Rheumatol; 2007 Apr; 13(2):73-8. PubMed ID: 17414533
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate.
    Maini RN; Breedveld FC; Kalden JR; Smolen JS; Furst D; Weisman MH; St Clair EW; Keenan GF; van der Heijde D; Marsters PA; Lipsky PE;
    Arthritis Rheum; 2004 Apr; 50(4):1051-65. PubMed ID: 15077287
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Lymphoma in patients with rheumatoid arthritis: association with the disease state or methotrexate treatment.
    Georgescu L; Quinn GC; Schwartzman S; Paget SA
    Semin Arthritis Rheum; 1997 Jun; 26(6):794-804. PubMed ID: 9213378
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Association of C35T polymorphism in dihydrofolate reductase gene with toxicity of methotrexate in rheumatoid arthritis patients.
    Vejnović D; Milić V; Popović B; Damnjanović T; Maksimović N; Bunjevački V; Krajinović M; Novaković I; Damjanov N; Jekić B
    Expert Opin Drug Metab Toxicol; 2019 Mar; 15(3):253-257. PubMed ID: 30583708
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.